TABLE 1.
Summary of the clinical trials evaluating MSCs.
| NCT Number | Condition | Phases | Type of product | Match | Route of administration | Dose (106 cells) | Cell expansion passage | Preconditioning | Status | Gender | Age (years) | Enrollment | Start date | Location | Funded bys | Study results |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04919135 | Frailty | Phase 1|Phase 2 | UC-MSCs | Allogenic | Intravenous | Not provided | — | — | Not yet recruiting | All | 60–85 | 44 | July 1, 2021 | Not provided | Other | Not available |
| NCT04453111 | Osteoarthritis | Phase 1|Phase 2 | BM-MSCs, P-MSCs | Autologous, Allogenic | intra-articular injection | Not provided | — | — | Recruiting | All | 18–75 | 45 | January 2, 2020 | Ukraine | Industry|Other | Not available |
| NCT03840343 | Diabetic Kidney Disease | Phase 1 | AD-MSCs | Autologous | intra-arterial | Not provided | — | — | Recruiting | All | 45–75 | 30 | October 23, 2019 | United States | Other | Not available |
| NCT04433104 | Chronic Obstructive Pulmonary Disease | Phase 1|Phase 2 | UC-MSCs | Allogenic | Intravenous | 1/kg | — | — | Recruiting | All | 40–75 | 40 | June 9, 2020 | Vietnam | Other | Not available |
| NCT04759105 | Chronic Low Back Pain | Phase 2 | BM-MSCs | Autologous | intradiscal injection | 15/disc | — | — | Recruiting | All | 18–65 | 52 | November 17, 2020 | Italy | Other | Not available |
| NCT03874572 | Dry Mouth Syndrome | Phase 1 | AD-MSCs | allogeneic | Intraglandular injection | Not provided | — | — | Active, not recruiting | All | 18–75 | 10 | March 18, 2019 | Denmark | Other | Not available |
| NCT03478215 | Kidney Transplantation | Phase 2 | MSCs | Autologous | Intravenous | 1 to 3/kg | — | — | Recruiting | All | 18–65 | 24 | February 2016 | United States | Other | Not available |
| NCT04356287 | Systemic Sclerosis | Phase 1|Phase 2 | UC-MSCs | Allogenic | Intravenous | 1/kg | — | — | Not yet recruiting | All | 18 and older | 18 | July 2021 | Not provided | Other | Not available |
| NCT03876197 | Radiation-induced Hyposalivation and Xerostomia | Phase 1|Phase 2 | AD-MSCs | Autologous | Intraglandular injection | Not provided | — | — | Enrolling by invitation | All | 18–99 | 30 | August 1, 2020 | Denmark | Other | Not available |
| NCT01586312 | Osteoarthritis | Phase 1|Phase 2 | BM-MSCs | Allogenic | intra-articular injection | 40 | 2 | — | Completed | All | 18–75 | 30 | April 2012 | Spain | Industry|Other | Allogeneic MSC therapy may be a valid alternative for the treatment of chronic knee osteoarthritis. doi: 10.1097/TP.0000000000000678 |
| NCT01860417 | Degenerative Disc Disease | Phase 1|Phase 2 | BM-MSCs | Allogenic | intradiscal injection | 25/disc | expanded ex vivo for 3–4 weeks | — | Completed | All | 18–75 | 25 | April 2013 | Spain | Industry|Other | Quick and significant improvement in algofunctional indices versus the controls. doi: 10.1097/TP.0000000000001484 |
| NCT03389919 | Graft Failure | Phase 3 | MSCs | Not provided | Intraosseous | Not provided | — | — | Recruiting | All | 18 and older | 20 | January 1, 2017 | Russian Federation | Other | Not available |
| NCT02195323 | Chronic Kidney Disease | Phase 1 | BM-MSCs | Autologous | Intravenous | Not provided | — | — | Completed | All | 25–60 | 7 | April 2014 | Iran | Other | Not available |
| NCT04325594 | Chronic Heart Failure | Phase 2 | UC-MSCs | Allogenic | intracoronary injection | 10 | — | — | Enrolling by invitation | All | 18 and older | 60 | March 1, 2020 | Kazakhstan | Other | Not available |
| NCT02495766 | Multiple Sclerosis | Phase 1|Phase 2 | BM-MSCs | Autologous | Intravenous | Not provided | — | — | Completed | All | 18–60 | 8 | May 11, 2015 | Spain | Other | Not available |
| NCT02384018 | Islet Autograft | Phase 1 | BM-MSCs | Autologous | Intravenous | 20 or 50 or 100 | — | — | Active, not recruiting | All | 18–69 | 42 | December 2014 | United States | Other|NIH | Not available |
| NCT02408432 | Heart Failure | Phase 1 | BM-MSCs | Allogenic | Intravenous | Not provided | — | — | Recruiting | All | 18–80 | 45 | January 11, 2016 | United States | Other|NIH | Not available |
| NCT03795974 | Cerebral Palsy | Phase 2 | UC-MSCs | Allogenic | intrathecal injection | Not provided | — | — | Unknown status | All | avr-14 | 108 | July 23, 2017 | Iran | Other | Not available |
| NCT02962661 | Heart Failure | Phase 1 | BM-MSCs | Allogenic | Intravenous | Not provided | — | — | Recruiting | All | 18–80 | 72 | July 18, 2020 | United States | Other|NIH | Not available |
| NCT03745417 | Psoriasis | Phase 1|Phase 2 | UC-MSCs | Allogenic | Intravenous | 2/kg | — | — | Not yet recruiting | All | 18–65 | 5 | August 31, 2021 | China | Other | Not available |
| NCT02801890 | Peritoneal Fibrosis | Phase 1|Phase 2 | AD-MSCs | Autologous | Intravenous | 1/kg | — | — | Completed | All | 18–70 | 10 | August 2015 | Iran | Other | Not available |
| NCT01275612 | Solid Organ Cancers | Phase 1 | MSCs | Not provided | Intravenous | 1/kg | — | — | Withdrawn | All | 18–80 | 0 | November 2010 | Italy | Other | Not available |
| NCT00781872 | Multiple Sclerosis | Phase 1|Phase 2 | BM-MSCs | Autologous | IV, Intrathecal | 1/kg | 40–60 days | — | Completed | All | 35–65 | 24 | October 2006 | Not provided | Other | Transplantation of MSCs in patients with MS and ALS is a clinically feasible and relatively safe procedure and induces immediate immunomodulatory effects. doi:10.1001/archneurol.2010.248 |
| NCT04869761 | Chronic Kidney Diseases | Phase 1 | AD-MSCs | Allogenic | Intravenous | 150 | — | — | Not yet recruiting | All | 40–80 | 40 | May 2021 | United States | Other | Not available |
| NCT03265613 | Psoriasis | Phase 1|Phase 2 | AD-MSCs | Allogenic | Intravenous | 0,5/kg | — | — | Active, not recruiting | All | 18–65 | 7 | September 24, 2017 | China | Other | Not available |
| NCT03392311 | Psoriasis | Phase 1|Phase 2 | AD-MSCs | Allogenic | Intravenous | 2/kg | — | — | Enrolling by invitation | All | 18–65 | 8 | August 17, 2019 | China | Other | Not available |
| NCT02646007 | Kienböck’s Disease | Phase 1 | BM-MSCs | Autologous | Injection | Not provided | — | — | Unknown status | All | 18–65 | 30 | November 2015 | Iran | Other | Not available |
| NCT03042143 | Acute Respiratory Distress Syndrome | Phase 1|Phase 2 | UC-CD362 enriched MSCs | Not provided | Infusion | 100, 200, 400 | — | — | Recruiting | All | 16 and older | 75 | January 7, 2019 | United Kingdom | Other | Not available |
| NCT00644410 | Hart Failure | Phase 1|Phase 2 | BM-MSCs | Autologous | intramyocardial injection | 77,5 | 2 | — | Completed | All | 30–80 | 59 | September 2008 | Denmark | Other | Expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure. doi:10.1093/eurheartj/ehv136 |
| NCT04519671 | Crohn’s Disease | Phase 1|Phase 2 | BM-MSCs | Allogenic | Direct injection | 75 | — | — | Recruiting | All | 18–75 | 40 | November 19, 2020 | United States | Other | Not available |
| NCT04785027 | Psoriasis | Phase 1|Phase 2 | AD-MSCs | Allogenic | Intravenous | 2/kg | — | — | Recruiting | All | 18–65 | 16 | March 17, 2021 | China | Other | Not available |
| NCT04371393 | Covid -19 Acute Respiratory Distress Syndrome | Phase 3 | remestemcel-L | Not provided | Intravenous | 2/kg | — | — | Active, not recruiting | All | 18 and older | 223 | April 30, 2020 | United States | Other|Industry|NIH | Not available |
| NCT03325322 | Chronic Kidney Disease | Phase 2 | Not provided | Not provided | Not provided | Not provided | — | — | Recruiting | All | 40–80 | 30 | January 2, 2018 | United States | Other | Not available |
| NCT02940418 | Diabetes | Phase 1 | AD-MSCs | Allogenic | Intravenous | 1/kg, 10/kg | 5 | — | Recruiting | All | 18–35 | 20 | February 19, 2017 | Jordan | Other | Not available |
| NCT00395200 | Multiple Sclerosis | Phase 1|Phase 2 | BM-MSCs | Autologous | Intravenous | 2/kg | — | — | Completed | All | 18–65 | 10 | July 2008 | United Kingdom | Other | The evidence of structural, functional, and physiological improvement after treatment in some visual endpoints is suggestive of neuroprotection. doi: 10.1016/S1474-4422(1170305-2) |
| NCT03042572 | No-option Severe Limb Ischemia | Phase 2|Phase 3 | BM-MSCs | Allogenic | Intramuscular injection | 150 | — | — | Not yet recruiting | All | 18 and older | 60 | December 2018 | Netherlands | Other | Not available |
| NCT02685098 | Amputation | Phase 1 | BM-MSCs | Allogenic | — | Not provided | — | — | Recruiting | All | 40–90 | 16 | January 2017 | United States | Other | Not available |
| NCT04447833 | Covid -19 Acute Respiratory Distress Syndrome | Phase 1 | BM-MSCs | Allogenic | Intravenous | 1/kg, 2/kg | — | — | Active, not recruiting | All | 18–65 | 7 | June 17, 2020 | Sweden | Other | Not available |
| NCT01468064 | Ischemic Stroke | Phase 1|Phase 2 | BM-MSCs and EPCs | Autologous | Intravenous | 2,5/kg | 33.75 days | — | Completed | All | 18–80 | 20 | November 2011 | China | Other|Industry | Autologous transplantation of EPCs appears to improve long-term safety in acute cerebral infarct patients. doi: 10.1002/sctm.18-0012 |
| NCT02379442 | Graft-Versus-Host-Disease | Phase 1|Phase 2 | BM-MSCs | Allogenic | Intravenous | 2 × 1/kg, 12 doses | — | — | Terminated | All | 4–99 | 1 | February 23, 2015 | United States | NIH | Not available |
| NCT02893306 | Diabetes | Phase 2 | BM-MSCs | Allogenic | Intravenous | 2–3/kg | — | — | Unknown status | All | 18 and older | 10 | March 2012 | Chile | Other | Not available |
| NCT02017912 | Amyotrophic Lateral Sclerosis | Phase 2 | BM-MSC-NTF | Autologous | Intramuscular and intrathecal | Not provided | — | induced to secrete NTFs by a medium based approach | Completed | All | 18–75 | 48 | May 2014 | United States | Industry | Not available |
| NCT03164083 | Osteoarthritis | Phase 2 | BM-MSCs, SVF | Autologous | intra-articular injection | Not provided | — | — | Withdrawn | All | 25–65 | 0 | November 10, 2019 | Iran | Other | Not available |
| NCT03015623 | Acute Kidney Injury | Phase 1|Phase 2 | MSCs | Allogenic | integrated into the renal replacement circuit | 250–750 | — | — | Active, not recruiting | All | 18 and older | 24 | June 20, 2017 | United States | Industry | Not available |
| NCT03211793 | Ulcers of Systemic Sclerosis | Phase 1|Phase 2 | BM-MSCs | Allogenic | Intramuscular | 50 | — | — | Unknown status | All | 18 and older | 20 | November 2018 | Netherlands | Other | Not available |
| NCT04466098 | Covid -19Acute Respiratory Distress Syndrome | Phase 2 | MSCs | Not provided | Intravenous | 300 | — | — | Active, not recruiting | All | 18–80 | 9 | July 30, 2020 | United States | Other | Not available |
| NCT02274428 | Premature Infants | Phase 1 | UC-MSCs | Not provided | — | Not provided | — | — | Completed | All | 23–34 | 9 | October 2014 | Korea | Other | Not available |
| NCT00927355 | Effect of Thiazolidinediones on Human Bone | Not Applicable | Pioglitazone | Not provided | — | Not provided | — | — | Completed | All | 18–80 | 10 | April 2009 | United States | Other | Insights into the deleterious effects of TZDs on bone quality in diabetics and support a model in which TZD-induced adipogenesis may be a significant influencing factor on osteoblast differentiation and function. doi: 10.1016/j.trsl.2012.08.006 |
| NCT04247945 | Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2|Phase 3 | MSCs | Not provided | — | Not provided | — | — | Recruiting | All | up to 65 Years | 120 | February 1, 2020 | China | Other | Not available |
| NCT01144962 | Crohn’s Disease | Phase 1|Phase 2 | BM-MSCs | Allogenic | Local injection | 10–30-90 | 2 | — | Completed | All | 18 and older | 21 | June 2010 | Netherlands | Other | Local administration of allogeneic MSCs was not associated with severe adverse events in patients with perianal fistulizing Crohn’s disease. Injection of 3 × 107 MSCs appeared to promote healing of perianal fistulas.doi: 10.1053/j.gastro.2015.06.014 |
| NCT03102879 | Periapical Periodontitis | Not Applicable | Encapsulated UC-MSCs in a biological scaffold | Allogenic | Conventional Root Canal Treatment | Not provided | — | — | Completed | All | 16–58 | 36 | September 23, 2016 | Chile | Other | Safety and efficacy evidence of the endodontic use of allogenic umbilical cord mesenchymal stem cells encapsulated in a plasma-derived biomaterial. doi: 10.1177/0022034520913242 |
| NCT01739504 | Osteoarthritis | Not Applicable | AD-MSCs | Autologous | Intra articular | — | — | — | Terminated | All | 18–80 | 10 | March 1, 2014 | United States | Industry | Not available |
| NCT03298399 | Sickle Cell Disease | Phase 1 | BM-MSCs | Autologous | Intravenous | 2/kg | 28 days | — | Withdrawn | All | déc-40 | 0 | December 21, 2017 | Not provided | Other|NIH | Not available |
| NCT02421484 | Septic Shock | Phase 1 | BM-MSCs | Allogenic | Intravenous | 0,3/kg, 1/kg, 3/kg | — | — | Completed | All | 18 and older | 9 | May 2015 | Canada | Other | The infusion of freshly cultured allogenic bone marrow-derived MSCs, up to a dose of 3 million cells/kg (250 million cells), into participants with septic shock seems safe. doi: 10.1164/rccm.201705-1006OC |
| NCT02145923 | Neutropenic Enterocolitis | Phase 1|Phase 2 | BM-MSCs | Allogenic | Intravenous | 1,5–2/kg | — | — | Unknown status | All | 18–65 | 16 | May 2014 | Russian Federation | Other | Not available |
| NCT03818737 | Osteoarthritis | Phase 3 | BM-MSCs, AD-MSCs, UC-MSCs | Autologous | Orthobiologic injection | Not provided | — | — | Active, not recruiting | All | 40–70 | 480 | March 28, 2019 | United States | Other | Not available |
| NCT02033525 | Degenerative Meniscus Injury | Phase 1|Phase 2 | XCEL-M-ALPHA | Autologous | — | Not provided | — | — | Completed | All | 40–60 | 20 | January 31, 2014 | Spain | Other | Not available |
| NCT02209311 | Maxilla Alveolar Process Reconstruction | Phase 1|Phase 2 | Oral mucosa-MSCs-tissue engineered construction | Autologous | Implantation | Not provided | 3–4 weeks | — | Unknown status | All | 20–60 | 12 | September 2014 | Russian Federation | Other | Not available |
| NCT04445220 | Acute Kidney Injury | Phase 1|Phase 2 | MSCs (SBI-101) | Allogenic | Integration | 250–750 | — | — | Recruiting | All | 18 and older | 22 | November 19, 2020 | United States | Industry | Not available |
| NCT01849159 | Pulmonary Emphysema | Phase 1|Phase 2 | BM-MSCs | Allogenic | Intravenous | 200 | — | Hypoxia (1% pxygen) | Withdrawn | All | 35–75 | 0 | March 2014 | Russian Federation | Other | Not available |
| NCT04629833 | Steroid-Refractory Acute Graft-Versus-Host Disease | Phase 3 | MSCs-MC0518 | Not provided | Intravenous | 1–2/kg | — | — | Not yet recruiting | All | 12 and older | 210 | June 30, 2021 | France, Germany, Poland, Spain | Industry | Not available |
| NCT04007081 | XRT Induced Xerostomia | Not Applicable | BM-MSCs | Autologous | Salivary Gland Autotransplantation | 50 | 2 weeks | — | Completed | All | 18–89 | 12 | October 18, 2019 | United States | Other | Not available |
| NCT03643614 | Post-Irradiation Vaginal-Rectal Fistula | Phase 1 | AD-MSCs | Autologous | Direct injecton | Not provided | — | — | Completed | Female | 20–75 | 16 | August 1, 2017 | Russian Federation | Other | Not available |
| NCT02630836 | Hip Fracture | Phase 1|Phase 2 | BM-MSCs | Allogenic | Surgical treatment | Not provided | — | — | Withdrawn | All | 70–85 | 0 | December 2015 | Not provided | Other | Not available |
| NCT02323477 | Myocardial Infarction | Phase 1|Phase 2 | UC-MSCs, BM-MSCs | Allogenic, Autologous | peri-infarct areas | UC-MSCs (23), BM-MSCs (700) | — | — | Terminated | Male | 30–80 | 46 | February 2, 2015 | Turkey | Other|Industry | Intramyocardial administration of HUC-MSCs in combination with CABG displayed higher scores in reducing the scar tissue and restoration of ventricular wall functions compared with autologous BM-MNCs. doi: 10.1007/s12015-015-9601-0 |
| NCT04173650 | Dystrophic Epidermolysis Bullosa | Phase 1|Phase 2 | Exosomes from BM-MSCs (AGLE-102) | Allogenic | — | 2 doses | — | — | Not yet recruiting | All | 6 and older | 10 | January 2022 | — | Industry | Not available |
| NCT04366063 | Covid-19 Related Acute Respiratory Distress Syndrome | Phase 2|Phase 3 | MSCs + Evs | — | Intravenous | 2 MSC infusions (100) + 2 EVs infusions | — | — | Recruiting | All | 18–65 | 60 | June 6, 2020 | Iran | Other | Not available |